Benzinga··Vandana SinghJ&J Wins FDA Nod for Multiple Myeloma Combo with Blockbuster 83% Survival Rate
FDA approves J&J's Tecvayli plus Darzalex Faspro for multiple myeloma with 83.3% three-year survival rate, expanding drug's label.
JNJPhase 3 clinical trialFDA approval